Rina Patel Trujillo, DO
Endocrinology, Diabetes & Metabolism · Albuquerque, NMNPI 1548421571
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $84,525 of the $99,953 with a category attached, or 84.6%. Lilly USA, LLC accounts for 96.1% of it on its own, with 15 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $341.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$96K
- Novo Nordisk$2K
- Insulet Corporation$673
- Medtronic$241
- Xeris Pharmaceuticals, Inc.$221
- Dexcom, Inc.$143
- plus $502 from 10 others
What the payments were for
- Consulting fees$2,0402%
- Speaking & faculty fees$84,52585%
- Travel & lodging$7,8388%
- Food & beverage$5,5506%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 219 | $96,027 |
| Novo Nordisk | 6 | $2,146 |
| Insulet Corporation | 28 | $673 |
| Medtronic | 5 | $241 |
| Xeris Pharmaceuticals, Inc. | 7 | $221 |
| Dexcom, Inc. | 6 | $143 |
| UCB, Inc. | 1 | $99 |
| Abbott | 4 | $96 |
| GSK | 5 | $94 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Astellas Pharma US Inc | 2 | $38 |
| Ascendis Pharma Endocrinology Inc | 2 | $38 |
| Tandem Diabetes Care, Inc. | 2 | $32 |
| Amgen | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$86,684
- Saxenda$2,040
- Omnipod$240
- MINIMED 780G$154
- GVOKE PFS$108
How this compares
$99,953 in reported general payments places this provider in the 95th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
See all endocrinology, diabetes & metabolism providers in New Mexico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 165 | $241,301 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 116 | $148,197 |
| TrulicityDulaglutide | 76 | $97,297 |
| TymlosAbaloparatide | 12 | $31,636 |
| OzempicSemaglutide | 22 | $30,501 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $28,194 |
| JardianceEmpagliflozin | 16 | $24,304 |
| FarxigaDapagliflozin Propanediol | 24 | $21,100 |
| Humulin R U-500Insulin Regular, Human | 11 | $15,789 |
| NovologInsulin Aspart | 43 | $11,579 |
| Testosterone | 50 | $11,493 |
| Omnipod 5 Dexg7g6 Intro(Gen 5)Insulin Pmp Cart,aut,g6/7,cntr | 16 | $9,045 |
| Gvoke Hypopen 2-PackGlucagon | 13 | $7,845 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $7,633 |
| Insulin Aspart | 41 | $7,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $96,027 | $344,829269 claims |
| Novo NordiskOzempic, Novolog | $2,146 | $42,08065 claims |
| Boehringer IngelheimJardiance | $19 | $24,30416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
Other endocrinology, diabetes & metabolism in Albuquerque
- Robert FerraroAlbuquerque$101K
- Jeremy GleesonAlbuquerque$46K
- David SchadeAlbuquerque$16K
- Mansi MehtaAlbuquerque$15K
- Matthew BouchonvilleAlbuquerque$7K
- Teodor DuroAlbuquerque$6K
- Ivan PinonAlbuquerque$5K
- Namrata JannareddyAlbuquerque$4K
- Anita Sloan-GarciaAlbuquerque$4K
- Lisa EreifejAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.